Menu
Recruiting NCT07410481

Trial of Acceptance and Mindfulness-based Exposure Therapy (AMBET) and Present Centered Therapy (PCT)

No phase Interventional PTSD - Post Traumatic Stress Disorder Cardiac Arrest (CA)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Acceptance and Mindfulness Based Exposure Therapy, Present-Centered Therapy.
Who it may be relevant to
Registry conditions: PTSD - Post Traumatic Stress Disorder, Cardiac Arrest (CA). Basic parameters: 18 years — 81 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Randomized Clinical Trial of Acceptance and Mindfulness-based Exposure Therapy (AMBET) and Present Centered Therapy (PCT)

Overview

The goal of this clinical trial is to learn if a new therapy called Acceptance- and Mindfulness-Based Exposure Therapy (AMBET) helps treat post-traumatic stress disorder (PTSD) in people who survived a cardiac arrest. This study will compare AMBET to another psychotherapy treatment called Present Centered Therapy (PCT) to see which therapy is more effective in treating PTSD. The main questions it aims to answer are: Does AMBET reduce PTSD symptoms in survivors of cardiac arrest? How do the benefits of AMBET compare to PCT? Participants will: * Be randomly assigned to receive either AMBET or PCT * Attend 12 hours of individual psychotherapy sessions over about 12 weeks * Complete short weekly surveys about their mood and behaviors online * Wear a Fitbit device to track sleep and activity during the study * Do brief homework assignments between sessions

Interventions

  • Behavioral Acceptance and Mindfulness Based Exposure Therapy
    Eight sessions of exposure therapy combined with mindfulness delivered via videoconferencing platform. AMBET will consist of 90-minute weekly sessions for 4 weeks, then every other week for 4 more sessions.
  • Behavioral Present-Centered Therapy
    Twelve 60-minute weekly sessions of psychotherapy delivered via videoconferencing platform.

Primary outcome measures

  • Change in PTSD symptoms over time [Time frame: Baseline, At 6 weeks, Post-treatment: Approximately 3 months and 6 months from intake]
Secondary outcome measures (1)
  • Change in depressive symptoms over time [Time frame: Baseline, At 6 weeks, Post-treatment: approximately 3 months and 6 months from intake]

Eligibility criteria

Inclusion criteria

  • Between 18 and 81 years old at the time of consent
  • Fluency in English
  • Medical history of cardiac arrest >3 months ago
  • Clinically elevated PTSD symptoms (Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score ≥25)
  • U.S. Resident

Exclusion criteria

  • Lifetime history of primary psychotic or bipolar disorders
  • Current substance use disorder (moderate or severe in the past 6 months)
  • Active suicidal ideation with some intent to act in past 12 months, and/or suicide attempt in past 24 months
  • Substantial cognitive impairment (Mini Mental Status Exam (MMSE) score <25)
  • Initiation of new psychotropic medication <3 months ago
  • Non-cardiac etiology of CA (drowning, bleeding, trauma, drug overdose, etc)
  • Terminal illness with life expectancy <1 year
  • Concurrent psychotherapy for PTSD

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Columbia University Irving Medical Center — New York

Identifiers

NCT: NCT07410481 · AAAV5860 · P30AG064198-06

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗